Oaktree Acquisition Corp. III Life Sciences
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| OAKTREE ACQUISITION CORP. III LIFE SCIENCES | |
| March 26, 2026 | /s/ Zaid Pardesi |
|---|---|
| Name: Zaid Pardesi Title: Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Aman Kumar Aman Kumar | Chairman of the Board of Directors | March 26, 2026 |
| /s/ Zaid Pardesi Zaid Pardesi | Chief Executive Officer and Director (Principal Executive Officer) | March 26, 2026 |
| /s/ George A. Martinez George A. Martinez | Chief Financial Officer (Principal Financial and Accounting Officer) | March 26, 2026 |
| /s/ Paul Meister Paul Meister | Director | March 26, 2026 |
| /s/ Alvin Shih Alvin Shih | Director | March 26, 2026 |
| /s/ David A. Berry David A. Berry | Director | March 26, 2026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.